Ampicillin/Sulbactam

Overview

Ampicillin/sulbactam is a parenteral potentiated aminopenicillin antibiotic used in dogs and cats when injectable broad-spectrum beta-lactam therapy is required. The combination pairs ampicillin with the beta-lactamase inhibitor sulbactam, extending ampicillin’s activity against certain beta-lactamase–producing bacteria and making it a useful alternative to amoxicillin/clavulanate when oral administration is not feasible.

In clinical practice, ampicillin/sulbactam is commonly used in hospitalized or critically ill small animal patients, such as those with sepsis, pneumonia, or other severe infections requiring parenteral treatment. It may also be selected for perioperative antimicrobial prophylaxis. The drug is typically administered by IV, IM, or SC injection at regular intervals.

Mechanism of Action (MOA): Ampicillin is a time-dependent, bactericidal beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis. Sulbactam acts primarily by inhibiting certain beta-lactamase enzymes, thereby protecting ampicillin from enzymatic degradation and expanding its antimicrobial spectrum. Sulbactam also exhibits limited intrinsic antibacterial activity and may contribute synergistically when combined with ampicillin.

Indications

In dogs and cats, ampicillin/sulbactam is indicated when parenteral broad-spectrum antimicrobial therapy is required, particularly in situations where oral administration is not possible or appropriate. The addition of sulbactam expands ampicillin’s activity against certain beta-lactamase–producing organisms, making this combination useful for moderate to severe infections in small animal patients.

• Serious systemic infections: Used for treatment of aerobic and anaerobic gram-positive and gram-negative bacterial infections when injectable therapy is required, especially in hospitalized or critically ill dogs and cats.
• Empirical therapy in critically ill patients: Commonly selected as part of initial empirical treatment for conditions such as sepsis or severe pneumonia, often in combination with another antimicrobial to enhance gram-negative coverage.
• Alternative to oral amoxicillin/clavulanate: Appropriate when infections would otherwise be treated with amoxicillin/clavulanate but oral administration is not viable (eg, patients that are NPO or vomiting).
• Surgical prophylaxis: May be used perioperatively to reduce the risk of surgical site infections when a parenteral aminopenicillin with beta-lactamase inhibition is indicated.

Dosage (Reference)

Dog

In dogs, ampicillin/sulbactam is administered parenterally when injectable broad-spectrum beta-lactam therapy is required. Doses are expressed as the combined total of ampicillin plus sulbactam. Dosing interval and route depend on infection severity and clinical status.

Cat

In cats, ampicillin/sulbactam is used parenterally for moderate to severe infections when oral antimicrobial therapy is not feasible. Doses are based on combined drug concentration and are similar to those used in dogs.

Warnings & Precautions

Ampicillin/sulbactam is generally well tolerated in dogs and cats when used appropriately, but careful consideration should be given to patient history, renal function, and route of administration. Most precautions relate to hypersensitivity reactions and altered drug handling in compromised patients.

• Hypersensitivity reactions: Contraindicated in dogs and cats with a history of severe hypersensitivity or anaphylaxis to penicillins. Cross-reactivity may occur in patients hypersensitive to other beta-lactam antibiotics, including cephalosporins and carbapenems.
• Renal impairment: Increased plasma concentrations and prolonged elimination have been documented in azotemic dogs. Dosage interval reduction may be required in dogs and cats with impaired renal function.
• Seizure threshold: High doses of penicillins may lower seizure threshold. Veterinary relevance is uncertain, but caution is advised when administering to patients receiving other drugs that may predispose to seizures.
• Injection-related reactions: IM administration may be painful due to the alkaline pH of the solution. IV administration may cause thrombophlebitis or phlebitis, particularly with repeated dosing.
• Use during pregnancy and lactation: Both ampicillin and sulbactam cross the placenta and are excreted in low concentrations in milk. Use only when the expected maternal benefit outweighs potential risks to the fetus or nursing offspring.
• Severe infections: In patients with high bacterial burden or organisms producing large amounts of beta-lactamase, clinical efficacy may be reduced despite beta-lactamase inhibition.

Drug Interactions

The following drug interactions with ampicillin/sulbactam have been reported or are theoretical in dogs and cats. Most interactions involve altered antimicrobial efficacy, changes in drug elimination, or increased risk of adverse effects. Concurrent use is not always contraindicated, but appropriate monitoring is recommended.

• Aminoglycosides (eg, gentamicin, amikacin): Beta-lactam antibiotics can inactivate aminoglycosides when mixed in vitro and potentially in vivo in patients with renal impairment. Administer separately and monitor renal function closely when used together.
• Bacteriostatic antimicrobials (eg, tetracyclines, macrolides, chloramphenicol, sulfonamides): In vitro antagonism with beta-lactam antibiotics has been reported, which may reduce bactericidal activity; clinical significance remains uncertain.
• Probenecid: Decreases renal tubular secretion of both ampicillin and sulbactam, resulting in prolonged serum concentrations and extended half-life.
• Methotrexate: Ampicillin may reduce renal excretion of methotrexate, increasing serum concentrations and risk of toxicity.
• Mycophenolate: Concurrent administration may reduce serum concentrations or therapeutic effects of mycophenolate.
• Warfarin: Concurrent use may reduce vitamin K production by intestinal flora and increase the risk of bleeding.
• Allopurinol: Increased incidence of skin rashes has been reported in humans; veterinary significance in dogs and cats is unknown.

Side Effects & Overdose

Side Effects

Adverse effects associated with ampicillin/sulbactam in dogs and cats are generally uncommon and similar to those reported with other penicillins. Most reactions are mild, but serious effects may occur, particularly with parenteral administration.

• Injection site reactions: IM injections may be painful due to the alkaline pH of the solution. IV administration may cause phlebitis or thrombophlebitis, especially with repeated dosing.
• Hypersensitivity reactions: Although infrequent, reactions may be severe and include urticaria, fever, facial swelling, or anaphylaxis, particularly following IV administration.
• Gastrointestinal effects: Vomiting or diarrhea may occur; alteration of intestinal flora can contribute to antibiotic-associated diarrhea.
• Neurologic effects: High doses or increased CNS penetration have been associated with neurotoxicity, including ataxia, particularly reported in dogs.
• Hepatic effects: Penicillins are not considered hepatotoxic, but transient elevations in liver enzymes have been reported in dogs. The clinical significance is usually limited.
• Cardiorespiratory signs (dogs): Tachypnea, dyspnea, edema, and tachycardia have been reported rarely.

Overdose

Ampicillin/sulbactam has a relatively wide margin of safety in dogs and cats. Overdose is most likely to occur with high parenteral doses or in patients with impaired renal function.

• Neurologic signs: Ataxia or other CNS effects may develop, particularly at high doses or in animals with conditions that increase CNS penetration.
• Gastrointestinal signs: Vomiting and diarrhea may occur following excessive exposure.
• Management: Treatment is supportive and includes discontinuation of the drug, monitoring neurologic status, and adjusting dosage or dosing interval as needed.

Key Notes

Practical clinical considerations that support appropriate use of ampicillin/sulbactam in dogs and cats without repeating previously stated safety or adverse effect information:

• Injectable alternative to potentiated oral therapy: Best suited for cases in which a beta-lactam/beta-lactamase inhibitor is indicated but oral administration is not possible.
• Dosing logistics: The need for administration every 6 to 8 hours makes this drug most practical for inpatient or closely monitored hospitalized patients.
• Role in empirical protocols: Commonly selected as an initial beta-lactam component in empirical treatment plans for critically ill dogs and cats.
• Gram-negative coverage limitations: While effective against many beta-lactamase–producing gram-positive and anaerobic organisms, additional antimicrobials are often required for robust gram-negative coverage.
• Culture-driven refinement: Empirical use should be reassessed once culture and susceptibility results are available to optimize antimicrobial selection.
• Stewardship considerations: Use should be limited to clearly justified clinical indications to reduce unnecessary exposure to critically important antimicrobials.